The government is now receiving ZyCoV-D, a needle-free anti-Covid vaccination, according to a statement released by Zydus Cadila on Wednesday.
“The company has started the supplies of its Covid-19 vaccine ZyCoV-D to the government of India against their order from its newly commissioned, state-of-the-art Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Changodar, Ahmedabad,” the company stated in a statement.
For the national anti-Covid immunization program, the government placed an order for 10 million doses of the vaccine last year. The business also intends to provide the vaccine for purchase on the market.
The world’s first plasmid DNA vaccination is called ZyCoV-D. It is a three-dose vaccine that must be applied intradermally using the painless, needle-free Tropis system from PharmaJet on days 0, 28, and 56.
The cost of the vaccine per dosage will be $265, and the cost of the applicator per dose will be $93 (excluding GST). The business announced that it has a contract manufacturing agreement in place with Shilpa Medicare Limited to manufacture doses of ZyCoV-D. It also has a contract for the manufacturing license and technology transfer of the vaccine with Enzychem Lifesciences of the Republic of Korea.
“Zydus VTEC produces the active ingredient for ZyCoV-D, the needle-free DNA Plasmid vaccine. Automated material transfers and production processes are used throughout the plant, according to a statement from Zydus.
The vaccine was approved for limited use in emergency conditions for adults 12 and older by the national medicines agency. The company has previously stated that it should be able to produce 10–12 million doses each month.
The Zydus vaccine will initially be deployed in Bihar, Jharkhand, Maharashtra, Punjab, Tamil Nadu, Uttar Pradesh, and West Bengal regions with low first-dose coverage, according to the Union Ministry of Health. Later, the vaccine will be distributed across the country.